| Literature DB >> 29843514 |
Katalin Prokai-Tatrai1, Vien Nguyen1, Laszlo Prokai1.
Abstract
Uterotrophic effect of 17α-estradiol, the C17 epimer of the main human estrogen 17β-estradiol, was shown to manifest in animal models at doses lower than those necessary for central outcome raising concerns about its potential to treat maladies of the central nervous system. We introduce here 10β,17α-dihydroxyestra-1,4-dien-3-one (α-DHED) that acts as a bioprecursor prodrug producing 17α-estradiol with remarkable selectivity to the brain and, therefore, without appreciable exposure of the periphery to the parent steroid. This distinguishing feature of α-DHED is shown by using an estrogen-responsive mouse model with complementary LC-MS/MS measurement of drug contents in target tissues. Our data warrant further research to fully establish the potential of α-DHED for a safe and efficacious 17α-estradiol-based neurotherapy.Entities:
Keywords: 10β,17α-dihydroxyestra-1,4-dien-3-one; 17α-Estradiol; ERs binding; LC-MS/MS; Porsolt swim test; brain-selective bioprecursor prodrug; ovariectomized mice; uterotrophic effect; α-DHED
Mesh:
Substances:
Year: 2018 PMID: 29843514 PMCID: PMC6582959 DOI: 10.1021/acschemneuro.8b00184
Source DB: PubMed Journal: ACS Chem Neurosci ISSN: 1948-7193 Impact factor: 4.418